156 related articles for article (PubMed ID: 32181600)
1. Identification of key genes and pathways of diagnosis and prognosis in cervical cancer by bioinformatics analysis.
Yang HJ; Xue JM; Li J; Wan LH; Zhu YX
Mol Genet Genomic Med; 2020 Jun; 8(6):e1200. PubMed ID: 32181600
[TBL] [Abstract][Full Text] [Related]
2. Screening and Discovery of New Potential Biomarkers and Small Molecule Drugs for Cervical Cancer: A Bioinformatics Analysis.
Qiu HZ; Huang J; Xiang CC; Li R; Zuo ED; Zhang Y; Shan L; Cheng X
Technol Cancer Res Treat; 2020; 19():1533033820980112. PubMed ID: 33302814
[TBL] [Abstract][Full Text] [Related]
3. Integrated Bioinformatics Analysis for Identification of the Hub Genes Linked with Prognosis of Ovarian Cancer Patients.
Li X; Wang Q; Wu Z; Zheng J; Ji L
Comput Math Methods Med; 2022; 2022():5113447. PubMed ID: 35047055
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatics and cheminformatics approaches to identify pathways, molecular mechanisms and drug substances related to genetic basis of cervical cancer.
Andalib KMS; Rahman MH; Habib A
J Biomol Struct Dyn; 2023; 41(23):14232-14247. PubMed ID: 36852684
[TBL] [Abstract][Full Text] [Related]
5. In silico analysis of differentially expressed genesets in metastatic breast cancer identifies potential prognostic biomarkers.
Kim J
World J Surg Oncol; 2021 Jun; 19(1):188. PubMed ID: 34172056
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Nuclear Encoded Mitochondrial Gene Networks in Cervical Cancer.
Meneur C; Eswaran S; Adiga D; S S; G NK; Mallya S; Chakrabarty S; Kabekkodu SP
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1799-1811. PubMed ID: 34181336
[TBL] [Abstract][Full Text] [Related]
7. The potential mechanism of Guizhi Fuling Wan effect in the treatment of cervical squamous cell carcinoma: A bioinformatics analysis investigation.
Wang X; Wang T; Jiang X; Ruan Y; Wang J; Qi C
Medicine (Baltimore); 2024 Feb; 103(5):e37153. PubMed ID: 38306566
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism of colorectal cancer and screening of molecular markers based on bioinformatics analysis.
Zhao J; Kuang D; Cheng X; Geng J; Huang Y; Zhao H; Yang Z
Open Life Sci; 2023; 18(1):20220687. PubMed ID: 37954103
[TBL] [Abstract][Full Text] [Related]
9.
Zhang YT; Xu LJ; Li L
Genet Test Mol Biomarkers; 2024 Jan; 28(1):10-21. PubMed ID: 38294357
[No Abstract] [Full Text] [Related]
10. A gene interaction network‑based method to measure the common and heterogeneous mechanisms of gynecological cancer.
Wang M; Li L; Liu J; Wang J
Mol Med Rep; 2018 Jul; 18(1):230-242. PubMed ID: 29749503
[TBL] [Abstract][Full Text] [Related]
11. Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer.
Nuncia-Cantarero M; Martinez-Canales S; Andrés-Pretel F; Santpere G; Ocaña A; Galan-Moya EM
Breast Cancer Res Treat; 2018 Apr; 168(3):613-623. PubMed ID: 29330624
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of differentially expressed genes in cervical cancer: insights from transcriptomic analysis.
Haojue Wang ; Xianyi Lu ; Ling Fang ; Qifeng Shi ; Yang X
Cell Mol Biol (Noisy-le-grand); 2023 Oct; 69(10):276-281. PubMed ID: 37953592
[TBL] [Abstract][Full Text] [Related]
13. Entrectinib a Plausible Inhibitor for Osteopontin (SPP1) in Cervical Cancer-Integrated Bioinformatic Approach.
Poleboyina PK; Alagumuthu M; Pasha A; Ravinder D; Pasumarthi D; Pawar SC
Appl Biochem Biotechnol; 2023 Dec; 195(12):7766-7795. PubMed ID: 37086377
[TBL] [Abstract][Full Text] [Related]
14. APLN: A potential novel biomarker for cervical cancer.
Chen Y; Lin X; Zheng J; Chen J; Xue H; Zheng X
Sci Prog; 2021; 104(2):368504211011341. PubMed ID: 33881940
[TBL] [Abstract][Full Text] [Related]
15. Bioinformatics identification of characteristic genes of cervical cancer via an artificial neural network.
Liu L; Huang L; Deng L; Li F; Vannucci J; Tang S; Wang Y
Chin Clin Oncol; 2024 Feb; 13(1):4. PubMed ID: 38453655
[TBL] [Abstract][Full Text] [Related]
16. Functional New Transcription Factors (TFs) Associated with Cervical Cancer.
Jiang Y; Chen S
J Healthc Eng; 2022; 2022():8381559. PubMed ID: 35126951
[TBL] [Abstract][Full Text] [Related]
17. The expression and clinical value of LRP11, FUBP1 and TET1 in cervical cancer.
Zhao X; Li S; Wen J; Li Y
Cell Mol Biol (Noisy-le-grand); 2023 Jul; 69(7):80-84. PubMed ID: 37715422
[TBL] [Abstract][Full Text] [Related]
18. Investigating the potential of Juglans regia phytoconstituents for the treatment of cervical cancer utilizing network biology and molecular docking approach.
Dua R; Bhardwaj T; Ahmad I; Somvanshi P
PLoS One; 2024; 19(4):e0287864. PubMed ID: 38626166
[TBL] [Abstract][Full Text] [Related]
19. Comparative Bioinformatics Characteristic of Bladder Cancer Stage 2 from Stage 4 Expression Profile: A Network-Based Study.
Zamanian Azodi M; Rezaei Tavirani M; Rostami-Nejad M; Rezaei-Tavirani M
Galen Med J; 2018; 7():e1279. PubMed ID: 34466446
[TBL] [Abstract][Full Text] [Related]
20. Predicting 3D Structure, Cross Talks, and Prognostic Significance of
Safi S; Badshah Y; Shabbir M; Zahra K; Khan K; Dilshad E; Afsar T; Almajwal A; Alruwaili NW; Al-Disi D; Abulmeaty M; Razak S
Front Oncol; 2021; 11():797007. PubMed ID: 35047407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
